comparemela.com

Xuebing Sun News Today : Breaking News, Live Updates & Top Stories | Vimarsana

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Highlights from early- and late-stage pipeline include combination data for cornerstone therapies BRUKINSA and tislelizumab early results for OX40 agonist BGB-A445 and BCL-2 inhibitor. | May 25, 2023

BeiGene Presentations at the 2023 ASCO Annual Meeting Reinforce Promise Across Oncology Portfolio

Highlights from early- and late-stage pipeline include combination data for cornerstone therapies BRUKINSA and tislelizumab early results for OX40 agonist BGB-A445 and BCL-2 inhibitor BGB-11417 BeiGene

vimarsana © 2020. All Rights Reserved.